Pancreatic Cancer Research

ResearcherAnhui Medical UniversityActive in the last 2 years

Yang Feng Wu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-0906-9667; OpenAlex author ID A5060189095, A5134578866. Sources: OpenAlex.

Their work

Papers
12 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
49
Papers, trials and grants by year

2016: 1 paper · 2017: 3 papers · 2018: 2 papers · 2019: none · 2020: 1 paper · 2021: none · 2022: none · 2023: none · 2024: 1 paper · 2025: 3 papers · 2026: 1 paper

Papers 12

  1. The Vitamin D3 Analog Calcipotriol Attenuates Pancreatic Cancer Malignancy via Downregulating Thrombospondin 1 in Pancreatic Stellate Cells. Co-author DOI 10.1155/mi/2632235↗
  2. Targeting ARPC1B + Cancer Stem Cells to Sensitise Pancreatic Cancer to Gemcitabine Treatment. Co-author DOI 10.1111/cpr.70125↗
  3. The feasibility and potential benefits of administering adjuvant chemotherapy in resected pancreatic cancer patients unable to promptly remove intraperitoneal … Co-author DOI 10.1186/s12885-025-14262-1↗
  4. Efficacy of second-line treatment for gemcitabine-refractory unresectable pancreatic cancer in a real-world setting. Co-author DOI 10.1186/s12885-025-14601-2↗
  5. [Short-term outcomes of the TRIANGLE operation after neoadjuvant chemotherapy in locally advanced pancreatic cancer]. Co-author DOI 10.3760/cma.j.cn112139-20230615-000234↗
  6. The Role of Stellate Cells in Pancreatic Ductal Adenocarcinoma: Targeting Perspectives. Co-author DOI 10.3389/fonc.2020.621937↗
  7. YY1 suppresses proliferation and migration of pancreatic ductal adenocarcinoma by regulating the CDKN3/MdM2/P53/P21 signaling pathway. Co-author DOI 10.1002/ijc.31173↗
  8. Association between NR5A2 and the risk of pancreatic cancer, especially among Caucasians: a meta-analysis of case-control studies. Co-author DOI 10.2147/ott.s157759↗
  9. Galectin-1-driven upregulation of SDF-1 in pancreatic stellate cells promotes pancreatic cancer metastasis. Co-author DOI 10.1016/j.canlet.2017.03.024↗
  10. Association between ERCC2 Lys751Gln polymorphism and the risk of pancreatic cancer, especially among Asians: evidence from a meta-analysis. Co-author DOI 10.18632/oncotarget.15394↗
  11. A novel messenger RNA signature as a prognostic biomarker for predicting relapse in pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.22861↗
  12. High-Level Expression and Prognostic Significance of Matrix Metalloprotease-19 and Matrix Metalloprotease-20 in Human Pancreatic Ductal Adenocarcinoma. First author DOI 10.1097/mpa.0000000000000569↗

Closest collaborators

The 25 strongest of 49 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kuirong Jiang · 7 shared papers, 2017–2025 · strength 0.83
  2. Jishu Wei · 3 shared papers, 2024–2025 · strength 0.68
  3. Min Tu · 3 shared papers, 2024–2025 · strength 0.68
  4. Yi Miao · 6 shared papers, 2017–2024 · strength 0.51
  5. Qianqian Wang · 2 shared papers, 2025 · strength 0.50
  6. Dong Xu · 2 shared papers, 2025 · strength 0.50
  7. Jan Goesta D’Haese · 2 shared papers, 2020–2026 · strength 0.42
  8. Pengfei Wu · 4 shared papers, 2017–2024 · strength 0.37
  9. Kuirong Jiang · 2 shared papers, 2018–2025 · strength 0.32
  10. Rainer Christoph Miksch · 1 shared paper, 2026 · strength 0.29
  11. Bernhard Willibald Renz · 1 shared paper, 2026 · strength 0.29
  12. Matthias Ilmer · 1 shared paper, 2026 · strength 0.29
  13. Maximilian Weniger · 1 shared paper, 2026 · strength 0.29
  14. Jens Werner · 1 shared paper, 2026 · strength 0.29
  15. Qi Li · 1 shared paper, 2026 · strength 0.29
  16. Guodong Shi · 4 shared papers, 2017–2018 · strength 0.27
  17. Kai Zhang · 1 shared paper, 2025 · strength 0.26
  18. Yi Miao · 1 shared paper, 2025 · strength 0.26
  19. Zipeng Lu · 4 shared papers, 2017–2018 · strength 0.25
  20. Wentao Gao · 1 shared paper, 2025 · strength 0.25
  21. Junli Wu · 1 shared paper, 2025 · strength 0.25
  22. Shaohui Xu · 1 shared paper, 2025 · strength 0.22
  23. Zhaokai Zhou · 1 shared paper, 2025 · strength 0.22
  24. Wenjie Shi · 1 shared paper, 2025 · strength 0.22
  25. Weixiong Zhu · 1 shared paper, 2025 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.